Loss narrows sharply. Lexicon Pharmaceuticals reported a Q4 2025 loss of $0.04 per share, narrower than the year-ago loss of $0.09 per share, marking a 55.56% improvement year-over-year. Revenue came in at $5.5 million for the quarter. The company posted a net loss of $15.5 million, with an operating loss of $14.8 million against gross profit of $5.3 million and cost of revenue of $201 million. Shares traded flat at $1.61 on volume of 2.4 million shares, within the day’s range of $1.57 to $1.66.
Revenue collapses year-over-year. The $5.5 million in quarterly revenue represents a dramatic 79.31% decline from the year-ago period. The biotechnology company’s gross margin remained strong at 96.3%, with cost of revenue representing just $201 million. The company held its earnings call at 8:30 AM ET on March 5, 2026, with both the press release and webcast replay available through its investor relations portal.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.